Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs

Area of Science:

• Biochemistry
• Organic Chemistry
• Pharmacology

Background:

• Cancer cells exhibit elevated reactive oxygen species (ROS) levels, a characteristic exploited for cancer-specific prodrug activation.
• Current ROS-dependent prodrug activation is often inefficient at low cellular concentrations of prodrugs and ROS.

Purpose of the Study:

• To develop a general approach to enhance the activation efficiency of ROS-dependent prodrugs.
• To create a lysosome-specific analogue of a known phenylboronic acid pinacol ester prodrug to improve ROS-mediated activation.

Main Methods:

• Modification of the parent prodrug 4-(N-ferrocenyl-N-benzylaminocarbonyloxymethyl)phenylboronic acid pinacol ester into a lysosome-specific derivative.
• Evaluation of prodrug activation efficiency in lysosomes due to higher ROS concentrations compared to the cytoplasm.
• Assessment of anticancer activity in vitro across various cancer cell lines and in vivo using a murine model.

Main Results:

• The lysosome-specific prodrug demonstrated facilitated activation compared to the parent compound.
• High anticancer activity was observed in multiple cancer cell lines with IC50 values ranging from 3.5-7.2 μm.
• Effective in vivo anticancer efficacy was shown in a murine model at a dosage of 40 mg/kg.
• The prodrug exhibited low toxicity towards non-malignant cells, with IC50 values between 15-30 μm.

Conclusions:

• Targeting lysosomes for ROS-dependent prodrug activation is a viable strategy to overcome activation inefficiencies.
• The developed lysosome-specific prodrug offers a promising therapeutic agent with potent anticancer effects and a favorable safety profile.